Management

Mr. Aselage has been Chief Executive Officer (CEO) since 2014 and a member of the Board of Directors of Retrophin, Inc. since 2012. During his tenure as CEO, Mr. Aselage has drawn upon more than 30 years of biopharmaceutical experience to lead the transformation of Retrophin. Following his appointment, Mr. Aselage solidified the Company's leadership, led an operational review of pipeline and commercial assets, and built a growth strategy around investigational and commercial therapies to bring long-term value to patients and shareholders.
 
Prior to his appointment , Mr. Aselage was Executive Vice President and Chief Business Officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, Mr. Aselage built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. Mr. Aselage worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat, and earlier in his career, held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi) and Bristol Laboratories. Mr. Aselage is also a member of the Board of Directors for Acer Therapeutics and Patara Pharma. Mr. Aselage received his B.S. in Biology from the University of Notre Dame, currently serves on the Advisory Council for the Department of Science at Notre Dame.

Mr. McFarlane has served as Chief Operating Officer of Retrophin, Inc. since 2016. Mr. McFarlane is responsible for the Company's daily operations with principal responsibility for several key functions, including commercial operations, business development, patient services, and program management. Prior to joining Retrophin, Mr. McFarlane held leadership roles at leading biopharmaceutical companies, including UCB Inc., Genzyme Inc., and Sangstat Medical Corporation. Most recently, Mr. McFarlane served as Vice President of UCB, where he was responsible for the Global Bone Business in collaboration with Amgen. Mr. McFarlane also served as Vice President and General Manager of the U.S. Immunology Business during his tenure at UCB. This was preceded by positions of increasing responsibility while at Genzyme and Sangstat. Mr. McFarlane served as an officer and enlisted soldier in the United States Army Reserves. Mr. McFarlane received his B.S. and M.S. in Nursing from the University of Florida.

Ms. Clague has served as Chief Financial Officer of Retrophin, Inc. since 2014. In overseeing the Company's financial operations, Ms. Clague has built and manages a team of finance and accounting professionals who have implemented financial systems and a lean infrastructure to support the organization. Ms. Clague brings to Retrophin more than 30 years of experience as a financial executive. Most recently, Ms. Clague served as Chief Financial Officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., after its acquisition by Bristol-Myers Squibb and subsequent divestiture to AstraZeneca. Prior to the acquisition, Ms. Clague was the Vice President, Corporate Controller and Principal Accounting Officer of Amylin for 10 years, when she also served as the Chief Financial Officer of Amylin's collaboration with Eli Lilly and Company. Earlier, Ms. Clague held financial roles at Sony Electronics, Inc., Cubic Corporation and KPMG. Ms. Clague currently serves on the board of directors of LRAD Corporation. Ms. Clague is a Certified Public Accountant in the State of California, and received a B.S. in Business Administration from Menlo College.

Ms. Reed has served as Senior Vice President, General Counsel and Corporate Secretary of Retrophin, Inc. since 2017. She is responsible for overseeing the Company's general legal, intellectual property, government affairs and corporate compliance functions. Previously, Ms. Reed served as General Counsel of Celladon Corporation, and prior to Celladon, served as General Counsel of Anadys Pharmaceuticals, Inc. until Anadys' acquisition by Roche. Prior to joining Anadys, she was an attorney with the law firms Cooley Godward LLP and Brobeck, Phleger & Harrison LLP. Ms. Reed is a member of the State Bar of California, and received her J.D. from Harvard Law School and her B.S. in Business Administration from the University of California at Berkeley.

Directors

Mr. Lyons has been a member of the Board of Directors of Retrophin, Inc. since 2014 and assumed the role of Chairman in May of 2016. Previously, Mr. Lyons was the founding President and Chief Executive Officer of Neurocrine Biosciences from 1993 to 2008 and remains as a member of the Board of Directors. Prior to his work at Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons currently serves as Chairman of the Board of Directors for Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases. He also serves as a Director for Vical Incorporated, a biotechnology company focused on the prevention and treatment of serious or life-threatening diseases, and Cytori Therapeutics, a company focused on stem cell therapies. Mr. Lyons was previously a director of PDL BioPharma, Inc., NeurogesX, Inc., and Facet Biotech Corporation. Mr. Lyons holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management.

Mr. Aselage has been Chief Executive Officer (CEO) since 2014 and a member of the Board of Directors of Retrophin, Inc. since 2012. During his tenure as CEO, Mr. Aselage has drawn upon more than 30 years of biopharmaceutical experience to lead the transformation of Retrophin. Following his appointment, Mr. Aselage solidified the Company's leadership, led an operational review of pipeline and commercial assets, and built a growth strategy around investigational and commercial therapies to bring long-term value to patients and shareholders.
 
Prior to his appointment , Mr. Aselage was Executive Vice President and Chief Business Officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, Mr. Aselage built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. Mr. Aselage worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat, and earlier in his career, held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi) and Bristol Laboratories. Mr. Aselage is also a member of the Board of Directors for Acer Therapeutics and Patara Pharma. Mr. Aselage received his B.S. in Biology from the University of Notre Dame, currently serves on the Advisory Council for the Department of Science at Notre Dame.

Dr. Baynes has been a member of the Board of Directors of Retrophin, Inc. since 2016. Currently, Dr. Baynes is senior vice president of Global Clinical Development at Merck Research Laboratories. Prior to his role at Merck, Dr. Baynes was senior vice president of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., which was preceded by his service at Amgen, Inc. as vice president of Global Clinical Development and therapeutic area head for Hematology/Oncology. Before joining Amgen, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. Dr. Baynes received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa, and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.

Mr. Coughlin has been a member of the Board of Directors of Retrophin, Inc. since 2015. Tim is currently a Vice President at Neurocrine Biosciences having served as their Chief Financial Officer from September 2006 to February 2017. Mr. Coughlin has developed expertise in corporate accounting, finance, and operations management of companies ranging in size from start-ups through Fortune 500. Prior to Neurocrine, he served as Vice President of Financial Services at CHI, a nationwide integrated healthcare delivery system. From 1989 to 1999, Mr. Coughlin served as a Senior Manager in the Health Sciences practice of Ernst & Young, and its predecessors. Mr. Coughlin currently serves on the Board of Directors of Fate Therapeutics, a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat severe, life-threatening diseases. Mr. Coughlin holds a Bachelor's in Accounting from Temple University and a Master's in International Business from San Diego State University.

Mr. Golding has been a member of the Board of Directors of Retrophin, Inc. since 2013. Mr. Golding brings to Retrophin more than 44 years of experience in finance and accounting. Most recently, from August 1994 until his retirement in September 2003, he served as Senior Vice President and Chief Financial Officer of Atlantic Mutual Insurance Company, where, among other responsibilities, he oversaw the organization's corporate investment portfolio. Before that, Mr. Golding spent 13 years in various management and executive positions at Atlantic Mutual Insurance Company, including Senior Vice President and Comptroller, Vice President and Comptroller and Vice President-Internal Audit. Prior to that, he served as Vice President of Ideal Mutual Insurance Company, Assistant Controller of AIG, and in various positions at Crum & Forster. Earlier in his career, Mr. Golding worked at the Robert Stigwood Organization and as an auditor for the independent accounting firm of Price Waterhouse (now PriceWaterhouseCoopers). Mr. Golding currently serves on the Boards of Directors of United Automobile Insurance Group and Hudson City Bancorp (Chair of Risk Committee). He is also a Trustee of the John A. Forster Trust. He previously served on the Board of Directors of Neurologix, Inc., Somerset Hills Bancorp and National Atlantic Holding Corporation. A graduate of St. John Fisher College, Mr. Golding holds an MBA from Fairleigh Dickenson University and is also a graduate of the Advanced Education Program at the Wharton School of the University of Pennsylvania. He is a retired CPA, as well as a member of the American Institute of CPAs and the New York State Society of CPAs.

Chair of the Audit Committee

Dr. Kozarich has been a member of the Board of Directors of Retrophin, Inc. since 2015. Dr. Kozarich has more than 35 years of experience in academia and the biopharmaceutical industry. He currently serves as Chairman of Ligand Pharmaceuticals, and Chairman and President of ActivX Biosciences. Prior to his role at ActivX, Dr. Kozarich was Vice President at Merck Research Laboratories where he was responsible for programs including antimicrobial drug discovery, enzymology, 5a-reductase biology, lipid biochemistry, nuclear receptors, ion channels and structural biology. Dr. Kozarich previously held professorships at the University of Maryland and Yale School of Medicine and currently serves as an adjunct professor of chemical physiology at the Scripps Research Institute. He was named Director of the Year for 2014 by the Corporate Directors Forum, has been honored as an American Cancer Society Faculty Research Awardee, and received the Distinguished Scientist Award of the San Diego Section of the American Chemical Society. Dr. Kozarich holds a Bachelor's of Science in chemistry from Boston College and a Ph.D. in biological chemistry from the Massachusetts Institute of Technology and was an NIH Postdoctoral Fellow at Harvard University.

Mr. Meckler has been a member of the Board of Directors of Retrophin, Inc. since 2014. Mr. Meckler is currently Chief Executive Officer and a Director of Cocrystal Pharma, Inc. a pharmaceutical company focused on the discovery of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Additionally, Mr. Meckler is a Director of QLT, Inc., an ultra-orphan ophthalmic biotechnology company based in Canada. Previously, Mr. Meckler was Managing Director of the Andra Group, a life sciences consulting firm and acted as a Director and Interim CEO of Cypress Bioscience Inc. after its acquisition by Royalty Pharma. He has also served as a Director of ClearFarma USA, Kyalin Bioscience and Alveolus Inc. Earlier in his career, Mr. Meckler held a series of positions at Pfizer Inc. in Manufacturing Systems, Market Research, Business Development, Strategic Planning and Corporate Finance, which included playing a significant role in acquisitions and divestitures. Mr. Meckler is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in Industrial Management and M.S. in Industrial Administration from Carnegie Mellon University. In addition, Mr. Meckler received a J.D. from Fordham University School of Law.